Table 1 Basic characteristics of the included patients.

From: Biliary stenting alone versus biliary stenting combined with 125I particles intracavitary irradiation for the treatment of advanced cholangiocarcinoma

Variables

Overall

PTBS group (n = 71)

PTBS + 125I group (n = 113)

p value

Gender (male/female)

118/66

43/28

75/38

0.424

Age (y)

68.9 ± 12.3

68.8 ± 14.1

68.9 ± 11.0

0.819

Location (HCCA/DCCA)

117/67

44/27

73/40

0.718

CA19-9 (ng/ml)

650.0 (0.6–2068)

886 (1.1–1967)

509.2 (0.6–2068)

0.358

CEA (ng/ml)

4.4 (0.9–490.5)

4.4 (1.0–490.5)

4.4 (0.9–490.5)

0.510

ALT (U/L)

131 (18–542)

106 (18–542)

149 (22–513)

0.001

AST (U/L)

134 (19–793)

98 (19–793)

158 (28–541)

<0.001

ALP (U/L)

487 (39–2556)

404 (102–1990)

553 (39–2556)

0.013

GGT (U/L)

484(4.1–2528)

406(47–1837)

534 (4.1–2528)

0.047

TBIL (µmol/L)

224.7 (5.8–706.2)

158 (5.8–551.5)

249.7 (14.1–706.2)

0.003

DBIL (µmol/L)

179.3 (3.0–649.0)

150 (3–424)

201.4 (5–649)

0.006

ALB (g/L)

34.3 (23.6–45.3)

34.6 (25.1–43.6)

34.2 (23.6–45.3)

0.669

PT-INR

1.03 (0.63–16.5)

1.1 (0.6–1.6)

1.0 (0.7–16.5)

0.234

NC (109/L)

4.5 (1.6–35.6)

4.8 (1.7–34.8)

4.3 (1.6–35.6)

0.236

LC (109/L)

1.3 (0.3–4.2)

1.2 (0.3–2.8)

1.4(0.4–4.2)

0.152

PLT (109/L)

241 (30–644)

252 (30–644)

237 (54–533)

0.817

CRP (mg/L)

16.4 (0.6–270.0)

16.3 (1.5–270.0)

16.4 (0.6–205.6)

0.332

The length of stay (d)

14 (3–47)

13 (3–47)

15 (4–34)

0.058

Hospital costs (CNY)

34,368 (5,533–64,267)

28,821 (14,442–64,267)

36,631 (5,533–61,928)

<0.001

Survival time (m)

9 (1–30)

7 (1–13)

12 (1–30)

<0.001

  1. PTBS percutaneous transhepatic biliary stenting, HCCA hilar cholangiocarcinoma, DCCA distal cholangiocarcinoma, CA19-9 carbohydrate antigen 19-9, CEA carcino-embryonic antigen, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase, GGT gamma-glutamyl transpeptidase, TBIL total bilirubin, DBIL direct bilirubin, ALB albumin, PT-INR prothrombin time-international normalized ratio, NC neutrophil count, LC lymphocyte count, PLT platelet count, CRP c-reactive protein.
Back to article page